B
ESPR

Braidwell’s Esperion Therapeutics ESPR Stock Holding History

Braidwell’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-895,949
Closed -$1.25M – 90
2023
Q2 		$1.25M Sell
895,949
-315,570
-26% -$441K 0.04% 80
2023
Q1 		$1.93M Sell
1,211,519
-2,181,886
-64% -$11.3M 0.06% 78
2022
Q4 		$21.1M Buy
+3,393,405
New +$24.3M 0.71% 50

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braidwell's ESPR Position: Q3 2023 in Review

Braidwell sold out of Esperion Therapeutics (ESPR) in Q3 2023, closing a stake of 895,949 shares — an estimated $1.25M sold.

Braidwell first reported a position in ESPR in Q4 2022 and held it in 3 quarters. The position peaked at $21.1M in Q4 2022. 122 funds tracked by Wall St. Rank hold ESPR as of Q3 2023.

  • Braidwell reported no remaining Esperion Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Braidwell sold 895,949 Esperion Therapeutics shares in Q3 2023, an estimated $1.25M.
  • Braidwell first reported a position in Esperion Therapeutics in Q4 2022 and held it in 3 quarters.
  • Braidwell's Esperion Therapeutics position peaked at $21.1M in Q4 2022.
  • 122 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2023.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.